Literature DB >> 19515141

Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA?

Jan Willem Cohen Tervaert1, Jan Damoiseaux.   

Abstract

During the first international workshop on antineutrophil cytoplasmic antibodies (ANCA), Copenhagen 25 and 26 January 1988, ANCA, as detected by the indirect immunofluorescence (IIF) technique, was extensively discussed. Cytoplasmic fluorescence pattern was found in patients with vasculitis. In contrast, perinuclear fluorescence pattern was found in vasculitis but also in many other inflammatory disorders. At the workshop, it was stated that IIF should be combined with an antigen-specific technique and capture and direct enzyme-linked immunosorbent assay techniques were discussed. In 1999/2003, an international consensus statement on testing and reporting on ANCA was published. For vasculitis, IIF was advocated as a screening assay, followed by an antigen-specific assay. In other non-vasculitic inflammatory diseases, only IIF on ethanol-fixed granulocytes was advocated. Recently, it was demonstrated that antigen-specific tests could be used as screening tests. Furthermore, it became clear that antigen-specific tests, in which antigens are directly coated to the solid phase, demonstrate highly variable sensitivities and specificities, whereas when capture or anchor technologies are used, more reproducible results are obtained. Based on these studies, we propose that the international consensus statement on ANCA should be revised.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515141     DOI: 10.1111/j.1600-0463.2009.02478.x

Source DB:  PubMed          Journal:  APMIS Suppl        ISSN: 0903-465X


  5 in total

Review 1.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

Review 2.  Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.

Authors:  Marc Hilhorst; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2015-05-08       Impact factor: 10.121

3.  Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis.

Authors:  Judith Land; Wayel H Abdulahad; Suzanne Arends; Jan-Stephan F Sanders; Coen A Stegeman; Peter Heeringa; Abraham Rutgers
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

4.  A Case of Crescentic Glomerulonephritis Complicated with Hypocomplementemic Urticarial Vasculitis Syndrome and ANCA-Associated Vasculitis.

Authors:  Marenao Tanaka; Norihito Moniwa; Tomohiro Mita; Toshiyuki Tobisawa; Tamaki Matsumoto; Atsushi Mochizuki; Tomohisa Yamashita; Toshiyuki Yano; Masato Furuhashi; Tetsuji Miura
Journal:  Case Rep Nephrol Dial       Date:  2017-11-27

5.  Systematic Histological Scoring Reveals More Prominent Interstitial Inflammation in Myeloperoxidase-ANCA Compared to Proteinase 3-ANCA Glomerulonephritis.

Authors:  Samy Hakroush; Ingmar Alexander Kluge; Philipp Ströbel; Peter Korsten; Désirée Tampe; Björn Tampe
Journal:  J Clin Med       Date:  2021-03-16       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.